Yayın Ağı
SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler
Frequency of germline pathogenic variants in breast cancer predisposition genes among young Turkish breast cancer patients
Breast Cancer Research and Treatment
, cilt.202, sa.2, ss.297-304, 2023 (SCI-Expanded)
What Has Changed in Patients Aged 65 and over Diagnosed with Breast Cancer during the COVID-19 Pandemic: A Single-Center Experience
Clinical outcome and characteristics of Turkish breast cancer patients during SARS-Cov-2 pandemic: Single center experience.
Sentinel lymph node biopsy with/without axillary dissection in clinically node-positive breast cancer after neoadjuvant chemotherapy
ANNALS OF SURGICAL ONCOLOGY
, cilt.29, sa.SUPPL 1, ss.69-70, 2022 (SCI-Expanded)
Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study
Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial
Pembrolizumab for Early Triple-Negative Breast Cancer
NEW ENGLAND JOURNAL OF MEDICINE
, cilt.382, sa.9, ss.810-821, 2020 (SCI-Expanded)
PlumX Metrics
- Citations
- Citation Indexes: 1915
- Policy Citations: 14
- Clinical Citations: 2
- Captures
- Readers: 1663
- Mentions
- Blog Mentions: 6
- News Mentions: 47
- References: 2
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes
Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer
A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)
Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)
Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
, cilt.7, sa.5, ss.1459-1464, 2014 (SCI-Expanded)
The access rate to diagnosis and treatment modalities in breast cancer patients in Turkey; multicenter observational study.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, cilt.16, sa.4, ss.664-71, 2011 (SCI-Expanded)
Correlation of high FDG uptake in PET/CT with poor prognosis in metastatic gastric adenocarcinoma.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.29, sa.15, 2011 (SCI-Expanded)
Primary breast mantle cell lymphoma with atypical relapse patterns.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, cilt.16, sa.1, ss.181-2, 2011 (SCI-Expanded)
A case of Kikuchi-Fujimoto disease misdiagnosed as Hodgkin's lymphoma: the importance of second opinion.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, cilt.14, sa.2, ss.309-11, 2009 (SCI-Expanded)
Outcome of metastatic colorectal cancer patients receiving second line chemotherapy in Marmara University Hospital
JOURNAL OF CLINICAL ONCOLOGY
, cilt.25, sa.18, 2007 (SCI-Expanded)
The role of adjuvant chemoradiotherapy (CRT) in Turkish patients with gastric carcinoma
JOURNAL OF CLINICAL ONCOLOGY
, cilt.25, sa.18, 2007 (SCI-Expanded)
Clinical outcome of node-negative (NN) breast cancer (BC) patients
JOURNAL OF CLINICAL ONCOLOGY
, cilt.25, sa.18, 2007 (SCI-Expanded)
The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'.
Annals of oncology : official journal of the European Society for Medical Oncology
, cilt.15, ss.211-7, 2004 (SCI-Expanded)
Treatment outcomes in non-small cell lung cancer (NSCLC) patients: Comparison between Marmara University, Istanbul, Turkey and Knoxville, Tennessee
ANNALS OF ONCOLOGY
, cilt.15, ss.195-196, 2004 (SCI-Expanded)
Clinical outcome of breast cancer (BC) patients (pts) with pT1N0M0 disease
ANNALS OF ONCOLOGY
, cilt.15, ss.68, 2004 (SCI-Expanded)
Progress in systemic therapy for breast cancer
EUROPEAN JOURNAL OF CANCER
, cilt.38, 2002 (SCI-Expanded)
Diğer Dergilerde Yayınlanan Makaleler
Neoplastic diseases prevalence in a turkish university hospital.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, cilt.8, sa.1, ss.45-8, 2003 (Scopus)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
Combined Analysis of the MF18-02/03 Neosentiturk Studies: Factors Predicting Recurrence in ycN0/ypN-positive Breast Cancer with Sentinel Lymph Node Biopsy - Or Targeted Axillary Dissection - Alone After Neoadjuvant Chemotherapy
24th Annual Meeting of The American Society of Breast Surgeons (ASBrS), Mississippi, Amerika Birleşik Devletleri, 26 - 30 Nisan 2023, (Özet Bildiri)
Clinical outcome and characteristics of Turkish breast cancer patients during SARSCov-2 pandemic: Single center experience.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 Haziran 2022, (Özet Bildiri)
Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 Haziran 2022, (Özet Bildiri)
Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 Mayıs 2020, cilt.38, (Özet Bildiri)
Clinical, Radiological and Pathological Findings in Breast Cancer Patients Younger than 30
Breastanbul 2018 3rd Breast Cancer Conference, İstanbul, Türkiye, 11 - 13 Ekim 2018, (Özet Bildiri)
Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results
43rd ESMO Congress (ESMO), Munich, Almanya, 19 - 23 Ekim 2018, cilt.29, ss.104-105, (Özet Bildiri)
High Ki67 levels are significantly correlated with 21-gene assay recurrence scores
10th European Breast Cancer Conference (EBCC), Amsterdam, Hollanda, 9 - 11 Mart 2016, cilt.57, (Özet Bildiri)
Clinical and pathologic characteristics of patients with breast cancer and a second non-breast primary tumor.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
Kişiye özel meme kanseri tedavisinde ki67 oranlarının Oncotype Dx skorlarıyla korelasyonu
18. Ulusal Cerrahi kongresi, İzmir, Türkiye, 23 - 27 Mayıs 2012, (Özet Bildiri)
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy followed by concurrent chemoradiotherapy with cisplatin in locally advanced stage III and IV nasopharyngeal cancer.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri)
High Ki67 Values Are Significantly Correlated with Oncotype DX Scores
8th European Breast Cancer Conference (EBCC), Vienna, Avusturya, 21 - 24 Mart 2012, cilt.48, (Özet Bildiri)
Immunohistochemically Defined T1N0 Breast Cancer Subgroups Have Different Clinical Outcomes. A Retrospective Turkish Oncology Group Study
32nd Annual San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 9 - 13 Aralık 2009, cilt.69, (Özet Bildiri)
Impact of dose reductions of platinum compounds on survival in stage IIIB/IV non-small cell lung cancer (NSCLC)
45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2009, cilt.27, (Özet Bildiri)
Results of randomized phase II trial combining Iressa (R) (gefitinib) and arimidex in women with advanced breast cancer (ABC). EORTC protocol 10021.
31st Annual San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 10 - 14 Aralık 2008, cilt.69, (Özet Bildiri)
Stage I (T1N0M0) breast cancer (BC): Pathological characteristics and clinical outcome
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.113, (Özet Bildiri)
Trastuzumab beyond progression in metastatic breast cancer
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.77, (Özet Bildiri)
Serum Her2 extracellular domain (ECD) levels, pAkt and pMAPK expressions as potential markers for response to trastuzumab(T)-based therapy in metastatic breast cancer (MBC) patients (PTS). A Turkish oncology group study
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.90-91, (Özet Bildiri)
Outcome of colon cancer patients receiving adjuvant chemotherapy in Marmara University Hospital
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.130, (Özet Bildiri)
Outcome of metastatic colorectal cancer patients receiving palliative chemotherapy in Marmara University Hospital
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.129, (Özet Bildiri)
Outcome of adjuvant treatment in turkish breast cancer (BC) patients (PTS): Single institution experience
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.109, (Özet Bildiri)
Association between presence of HPV DNA and P53 in breast cancer patients
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.110-111, (Özet Bildiri)
Outcome of patients with stage III and IV non-small cell lung cancer in Marmara University Hospital, Istanbul, Turkey
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.225-226, (Özet Bildiri)
VEGF, HIF-1 alpha and CD34 expressions in gastric tumors (tms): Relationship with pathological factors and prognostic impact on survival.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, Amerika Birleşik Devletleri, 13 - 17 Mayıs 2005, cilt.23, (Özet Bildiri)
Outcome of adjuvant treatment in elderly Turkish breast cancer patients.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, Amerika Birleşik Devletleri, 13 - 17 Mayıs 2005, cilt.23, (Özet Bildiri)
The prognostic impact of body mass index (BMI) in early breast cancer (BC) patients (pts).
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, Amerika Birleşik Devletleri, 13 - 17 Mayıs 2005, cilt.23, (Özet Bildiri)
Clinical and pathological characteristics of early breast cancer (EBC) patients < 35 years old.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, Amerika Birleşik Devletleri, 13 - 17 Mayıs 2005, cilt.23, (Özet Bildiri)
Effects of taxanes alone or in combination with anthracyclines on tumor response, progression-free survival and overall survival in first-line chemotherapy of patients with metastatic breast cancer: an analysis of 4,256 patients randomized in 12 trials
28th Annual San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 8 - 11 Aralık 2005, cilt.94, (Özet Bildiri)
A quantitative study of tumor response and progression-free survival as surrogate endpoints for overall survival in first-line treatment of metastatic breast cancer
28th Annual San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 8 - 11 Aralık 2005, cilt.94, (Özet Bildiri)
The expression pattern of members of the EGFR signaling pathway and its relation with the duration of response in metastatic breast cancer (BC) patients (pts) treated with endocrine therapy (ET)
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, Amerika Birleşik Devletleri, 5 - 08 Haziran 2004, cilt.22, (Özet Bildiri)
Human papilloma virus: Is it a new etiological factor in breast cancer?
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, Amerika Birleşik Devletleri, 5 - 08 Haziran 2004, cilt.22, (Özet Bildiri)
FOLFOX4 in metastatic colorectal cancer (MCRC) patients who progressed after infusional 5-FU/irinotecan based combination regimens.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, Amerika Birleşik Devletleri, 5 - 08 Haziran 2004, cilt.22, (Özet Bildiri)
Prognostic value of thymidylate synthase and cox-2 expression in colorectal cancer patients' tumors.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, Amerika Birleşik Devletleri, 5 - 08 Haziran 2004, cilt.22, (Özet Bildiri)
Clinical outcome of breast cancer patients with liver metastases in the anthracycline-taxane era.
25th San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 11 - 14 Aralık 2002, cilt.76, (Özet Bildiri)
An EORTC IDBBC-ECSG randomized phase II trial of two different schedules of Caelyx (TM) in metastatic breast cancer patients.
25th San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 11 - 14 Aralık 2002, cilt.76, (Özet Bildiri)
